Target Validation and Biomarker Identification in Oncology: The Example of Aurora Kinases

ISSN： 1177-1062

Source： Molecular Diagnosis & Therapy, Vol.12, Iss.2, 2008-01, pp. : 71-76

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Target Validation to Biomarker Development: Focus on RNA Interference

By Colombo Riccardo Moll Jürgen

Molecular Diagnosis & Therapy, Vol. 12, Iss. 2, 2008-01 ,pp. : 63-70

Adis International

Access to resources Recommend Favorite

The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme

Oncology, Vol. 84, Iss. 6, 2013-04 ,pp. : 326-335

Karger

Access to resources Recommend Favorite

Impact of biomarker usage on oncology drug development

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 38, Iss. 1, 2013-02 ,pp. : 62-67

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of biomarker usage on oncology drug development

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 269-4727, Iss. 1, 2013-02 ,pp. : 62-67

John Wiley & Sons Inc

Access to resources Recommend Favorite

Target biomarker profile for the clinical management of paracetamol overdose

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 3, 2015-09 ,pp. : 351-362

John Wiley & Sons Inc

Access to resources Recommend Favorite